Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly (LLY) ended the recent trading session at $762.18, demonstrating a -1.23% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14% ...

Eli Lilly (NYSE: LLY) fourth-quarter performance exceeded the street expectations, with the company delivering adjusted earnings of $5.32 per share versus the projected $4.95.

Eli Lilly's stock isn't cheap The company's stock trades at a hefty 39 times forward earnings. That's very high for a pharma company and more than twice its main GLP-1 competitor, Novo Nordisk .

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Leerink Partners analyst David Risinger has reiterated their bullish stance on LLY stock, giving a Buy rating today. Geoff Meacham has given his Buy rating due to a combination of factors ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Eli Lilly (NYSE:LLY) is scheduled to release its earnings report on Thursday, May 1, 2025. For event-driven traders, historical stock performance following earnings announcements may offer ...

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a ...

Eli Lilly (LLY 0.16%) stock has soared 90% over the past year, ... Lilly's recent earnings and stock performance successes have left it trading for 62x times forward earnings estimates.

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...